A new study shows that a 70-year-old malaria drug can block immune cells in the liver so nanoparticles can arrive at their intended tumor site, overcoming a significant hurdle of targeted drug delivery, according to a team of researchers led by Houston Methodist.
Many cancer patients do not respond to chemotherapies because the drugs never reach the cancer cells. Even in nanomedicine, which is one of the best new methods for delivering drugs to a tumor, only about one percent of a dose of nanoparticles will successfully arrive at the intended tumor site, while the rest are filtered out by the immune cells of the liver and spleen.
Using chloroquine, the researchers not only increased the circulation of nanoparticles in the body, but also reduced the body’s filtration of nanoparticles, as well as improved drug delivery to breast tumors. The study was recently published in Scientific Reports, a research journal from the Nature Publishing Group.
Led by Mauro Ferrari, Ph.D., president and CEO of the Houston Methodist Research Institute, and Joy Wolfram, Ph.D. (now at Mayo Clinic’s campus in Jacksonville, Florida), the research showed that chloroquine interfered with immune cells called macrophages, which are used by the body to identify microscopic foreign objects and destroy them.
In this study, mice models received injections of chloroquine, followed by an injection of nanoparticles. Chloroquine decreased the macrophages’ ability to clean up the nanoparticles. The findings are significant, because the nanoparticles not only remained in circulation, but also accumulated in mouse tumors, as well as in the lungs of healthy mice, suggesting that the approach also may enhance treatment for lung diseases.
Chloroquine was invented in the 1940s for the prevention and treatment of malaria. Since it mildly suppresses the immune system, the drug also is used in some autoimmune disorders, such as rheumatoid arthritis and lupus. Apart from this research, the drug is also being studied in other cancers, such as triple-negative breast cancer and pancreatic cancer.
Ferrari, considered one of the founders of nanomedicine and transport oncophysics (the physics of mass transport within a cancer lesion), says researchers and clinicians need to understand the limitations of transport mechanisms to identify effective immunotherapy treatments for patients.
The Latest on: Drug delivery
[google_news title=”” keyword=”drug delivery” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Oregon House passes bill to reintroduce criminal penalties for drug possessionon March 3, 2024 at 5:35 am
The bill will also change the definition of drug delivery charges, enhance charges for dealers selling near treatment facilities, homeless shelters and public parks, and expand welfare holds from 48 ...
- Nanotechnology in Therapeuticson March 2, 2024 at 4:00 pm
Although progress in the application of nanotechnology to drug delivery has been dramatic and successful, as evidenced by some nanodrugs now on the market, several main challenges remain in this ...
- Nanotechnology in Therapeuticson February 29, 2024 at 4:00 pm
Nanomedicine. 2012;7(8):1253-1271. Liposomes Liposomes are self-assembled artificial vesicles developed from amphiphilic phospholipids. These vesicles consist of a spherical bilayer structure ...
- Novaxs provides details on its needle-free drug delivery platformon February 29, 2024 at 4:00 pm
In the first patenting from Chicago-based Novaxs Biotech Corp., its co-founders, Alina Rui Su and Jonathan Tianyi Xing, describe an injection system for needle-free, high-pressure drug delivery.
- Founder of New York narcotics delivery service gets 12 years for causing 3 overdose deathson February 28, 2024 at 7:29 pm
The founder of a New York drug delivery service was sentenced for his role in distributing cocaine laced with fentanyl that killed three people.
- Drug delivery articles from across Nature Portfolioon February 28, 2024 at 3:59 pm
Drug delivery describes the method and approach to delivering drugs or pharmaceuticals and other xenobiotics to their site of action within an organism, with the goal of achieving a therapeutic ...
- First product based on LTS Sorrel™ wearable drug delivery platform launched in the USon February 28, 2024 at 4:00 am
LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company, announced today that its customer Coherus BioSciences, Inc ("Coherus") has launched its UDENYCA® on-body injector ...
- Long-Acting Drug Delivery Technologies and Services Market Predicted to Reach $36.82 Billion by 2033, as Asia-Pacific Emerges with Highest CAGRon February 28, 2024 at 1:56 am
Acting Drug Delivery Technologies and Services Market: A Global and Regional Analysis, 2023-2033" report has been added to ResearchAndMarkets.com's offering. The global long-acting drug delivery ...
- Hydrogel-based Drug Delivery System Market Foresees Strong Growth, Targeting US$16.8 Billion Valuation by 2032on February 27, 2024 at 11:29 pm
Hydrogel-based Drug Delivery System MarketAccording to a recent industry study report by Future Market Insights, the hydrogel-based drug delivery systems market is expected to grow from its current ...
- Researchers design novel drug delivery system that could reverse Alzheimer's disease impacton February 21, 2024 at 2:22 pm
University of North Carolina at Chapel Hill researchers have developed a new drug delivery platform that harnesses helical amyloid fibers designed to untwist and release drugs in response to body ...
via Google News and Bing News